Market news
GOOGL, MA and ABBV headline today's research, with AI-led growth, electronic payments and strong drug portfolios shaping their outlooks.
ICCC's Q2 sales rise 11.5% y/y, but margins contract. A $2-million legal settlement boosts profit as the company plans a capacity expansion.
Detailed price information for Immucell Corp (ICCC-Q) from The Globe and Mail including charting and trades.
Moby summary of ImmuCell Corporation's Q2 2026 earnings call
ImmuCell (NASDAQ:ICCC) reported higher second-quarter sales and earnings as domestic demand for its calf scours prevention products increased, while the company outlined plans to invest about $8 million to more than triple manufacturing capacity by the end of 2027. Product sales rose 11.5% year ove
Detailed price information for Immucell Corp (ICCC-Q) from The Globe and Mail including charting and trades.
Detailed price information for Immucell Corp (ICCC-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.